

ADVENTRX PHARMACEUTICALS INC

Form 10-Q/A

October 30, 2006

**Table of Contents**

**SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 10-Q/A  
Amendment No. 1**

**(Mark One)**

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES  
EXCHANGE ACT OF 1934**

**For the quarterly period ended June 30, 2006**

**OR**

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES  
EXCHANGE ACT OF 1934**

**For the Transition Period from            to  
Commission File Number 001-32157**

**ADVENTRX Pharmaceuticals, Inc.**  
(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of incorporation or  
organization)

**84-1318182**  
(I.R.S. Employer Identification No.)

**6725 Mesa Ridge Road, Suite 100  
San Diego, California 92121  
858-552-0866**

(Address of principal executive offices, zip code and telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of "accelerated filer and large accelerated filer" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer  Accelerated filer  Non-accelerated filer

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

The number of shares outstanding of the registrant's common stock, \$.001 par value, as of July 31, 2006 was 73,562,298.

**Table of Contents**

**EXPLANATORY NOTE**

ADVENTRX Pharmaceuticals, Inc. (the Company) is filing this Amendment No. 1 to its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2006, filed with the Commission on August 9, 2006, solely to add Exhibits 4.1 and 4.2 and the required disclosure under Part II, Item 5 (Other Information), which were inadvertently omitted.

Except as described above, this Amendment No. 1 on Form 10-Q/A does not modify or update any information reported in the original Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2006, and it does not reflect events occurring after the date of filing of that original Quarterly Report. This Form 10-Q/A should be read in conjunction with the Company's other filings with the Commission subsequent to the filing of the original Quarterly Report.

---

**TABLE OF CONTENTS**

PART II OTHER INFORMATION

Item 5. Other Information

Item 6. Exhibits

Signatures

Exhibit Index

EXHIBIT 4.1

EXHIBIT 4.2

EXHIBIT 31.1

EXHIBIT 31.2

---

**Table of Contents**

**PART II OTHER INFORMATION**

**Item 5. Other Information**

On April 6, 2006, our Board of Directors extended the termination date of a common stock purchase warrant we issued to M. Ross Johnson, the Company's Chairman, on June 10, 1999. The warrant was originally set to expire on June 9, 2006. As amended, this warrant will terminate as of 5:01 p.m. on December 31, 2006. The warrant was not otherwise modified. Mr. Johnson was effectively unable to exercise this warrant during its original term as a result of a series of "black-out" periods to which he was subject as one of our directors. We believed it was inappropriate to penalize Mr. Johnson financially for his long-term service to us as a director. The change in value of the warrant due to the extension of its termination date was insignificant. The warrant, as amended, is filed as Exhibit 4.1 to this Quarterly Report.

On May 1, 2006, our Board of Directors recognized that, due to an administrative oversight, a warrant to purchase 50,000 shares of our common stock at an exercise price of \$2.50 per share issued to Emisphere Technologies, Inc. had not been delivered to Emisphere. On May 1, 2006, our Board of Directors ratified the issuance of this warrant and directed management to deliver the warrant to Emisphere. Michael M. Goldberg, M.D., the chairman and chief executive officer of Emisphere, is a member of our Board of Directors. The warrant is filed as Exhibit 4.2 to this Quarterly Report.

**Item 6. Exhibits**

An Exhibit Index has been attached as part of this Form 10-Q/A and is incorporated herein by reference

---

**Table of Contents**

**Signatures**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ADVENTRX Pharmaceuticals, Inc.

Date: October 27, 2006

By: /s/ Evan M. Levine  
Chief Executive Officer

ADVENTRX Pharmaceuticals, Inc.

Date: October 27, 2006

By: /s/ Robert A. Daniel  
Acting Chief Financial Officer and  
Treasurer

---

**Table of Contents**

**Exhibit Index**

**Exhibit Description**

- 2.1(3) Agreement and Plan of Merger, dated April 7, 2006, by and among the Registrant, Speed Acquisition, Inc., SD Pharmaceuticals, Inc. and certain individuals named therein (including exhibits thereto)
- 3.1(1) Amended and Restated Certificate of Incorporation
- 3.2(2) Amended and Restated Bylaws
- 4.1 Warrant to Purchase Common Stock issued on June 10, 1999 to M. Ross Johnson, as amended
- 4.2 Warrant to Purchase Common Stock issued on April 12, 2002 to Emisphere Technologies, Inc.
- 10.1(4) Compensation payable to our directors for their service on our board and associated committees, effective as of May 15, 2006
- 31.1 Rule 13a-14(a)/15d-14(a) Certification
- 31.2 Rule 13a-14(a)/15d-14(a) Certification
- (1) Incorporated by reference to our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 16, 2006.
- (2) Incorporated by reference to our Registration Statement on Form 10-SB filed with the Securities and Exchange Commission on October 2, 2001.
- (3) Incorporated by reference to our Current Report on Form 8-K/A filed with the

Securities and  
Exchange  
Commission on  
May 1, 2006.

- (4) Incorporated by  
reference to our  
Current Report  
on Form 8-K  
filed with the  
Securities and  
Exchange  
Commission on  
June 23, 2006.